Xiangdong Guan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiangdong Guan has a total of 252 co-authors. Here are the top co-authors by number of shared publications:
- Jianfeng Wu
Department of Critical Care Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
15 shared publications Jianfeng Wu
Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, Guangdong, China
12 shared publicationsChuanxi Chen
Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
7 shared publicationsHao Yuan
Medical Affairs Office, Tianhe District Maternal and Child Health Care Hospital, Guangzhou, China
7 shared publicationsNing Liu
Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
7 shared publicationsXiang Si
Department of Critical Care Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
7 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by Springer Nature in Critical Care
- Vol. 30 (1) , 430
Assessing fluid responsiveness in mechanically ventilated patients with intra-abdominal hypertension: a two-center, prospective, observational study
Intra-abdominal hypertension (IAH) may reduce the diagnostic accuracy of the passive leg raising (PLR) test for predicting fluid responsiveness, with uncle
- 17 July 2026
- Published by Springer Nature in Critical Care
- Vol. 30 (1) , 430
Open AccessAssessing fluid responsiveness in mechanically ventilated patients with intra-abdominal hypertension: a two-center, prospective, observational study
Intra-abdominal hypertension (IAH) may reduce the diagnostic accuracy of the passive leg raising (PLR) test for predicting fluid responsiveness, with uncle
- 15 May 2026
- Published by Elsevier in Journal of Intensive Medicine
- Vol. 6 (4) , 410-412
Corrigendum to “The current situation of intensive care units in Chinese mainland: A nationwide survey” [Journal of Intensive Medicine volume 2 (2026) 132–140]
- 15 May 2026
- Published by Elsevier in Journal of Intensive Medicine
- Vol. 6 (4) , 410-412
Corrigendum to “The current situation of intensive care units in Chinese mainland: A nationwide survey” [Journal of Intensive Medicine volume 2 (2026) 132–140]
- Open Access
- 28 March 2026
- Published by Elsevier in Journal of Intensive Medicine
- Vol. 6 (3) , 247-254
Efficacy and safety of remimazolam tosylate for sedation in ICU patients: A multicenter, randomized, phase 2 study
- 28 March 2026
- Published by Elsevier in Journal of Intensive Medicine
- Vol. 6 (3) , 247-254
Open AccessEfficacy and safety of remimazolam tosylate for sedation in ICU patients: A multicenter, randomized, phase 2 study
- Open Access
- 5 February 2026
- Published by Elsevier in Journal of Intensive Medicine
- Vol. 6 (2) , 132-140
The current situation of intensive care units in Chinese mainland: A nationwide survey
- 5 February 2026
- Published by Elsevier in Journal of Intensive Medicine
- Vol. 6 (2) , 132-140
Open AccessThe current situation of intensive care units in Chinese mainland: A nationwide survey
- Open Access
- 22 January 2026
- Published by Elsevier in Journal of Intensive Medicine
- Vol. 6 (3) , 197-213
Practice guideline on the prevention and treatment of central line-associated bloodstream infection: Part 2 – Treatment
- 22 January 2026
- Published by Elsevier in Journal of Intensive Medicine
- Vol. 6 (3) , 197-213
Open AccessPractice guideline on the prevention and treatment of central line-associated bloodstream infection: Part 2 – Treatment
- Open Access
- 22 January 2026
- Published by Elsevier in Journal of Intensive Medicine
- Vol. 6 (2) , 83-92
Practice guideline on the prevention and treatment of central line-associated bloodstream infection: Part 1––Diagnosis and prevention
- 22 January 2026
- Published by Elsevier in Journal of Intensive Medicine
- Vol. 6 (2) , 83-92
Open AccessPractice guideline on the prevention and treatment of central line-associated bloodstream infection: Part 1––Diagnosis and prevention
- Top Cited PapersOpen Access
- 22 January 2026
- Published by Springer Nature in Critical Care
- Vol. 30 (1) , 35
Fluid responsiveness and changes in venous congestion and lung water during volume expansion in critically ill patients: a multicentre observational study
The relationship between fluid responsiveness and right-and left-sided congestion remains underexplored. This study aimed to delineate the dynamic behaviou
- 22 January 2026
- Published by Springer Nature in Critical Care
- Vol. 30 (1) , 35
Top Cited PapersOpen AccessFluid responsiveness and changes in venous congestion and lung water during volume expansion in critically ill patients: a multicentre observational study
The relationship between fluid responsiveness and right-and left-sided congestion remains underexplored. This study aimed to delineate the dynamic behaviou
- Open Access
- 30 December 2025
- Published by Elsevier in Journal of Intensive Medicine
- Vol. 6 (1) , 1-15
Guidelines for the construction and management of critical care medicine in China (2025 Edition)
- 30 December 2025
- Published by Elsevier in Journal of Intensive Medicine
- Vol. 6 (1) , 1-15
Open AccessGuidelines for the construction and management of critical care medicine in China (2025 Edition)
- Open Access
- 4 November 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2580058
Effect of nafamostat mesylate anticoagulation and regional citrate anticoagulation during continuous renal replacement therapy in critically ill patients: a retrospective study of efficacy and safety
Regional citrate anticoagulation (RCA) is recommended for critically ill patients at high bleeding risk undergoing continuous renal replacement therapy (CRRT). Nafamostat mesylate (NM), a short-half-life serine protease inhibitor, is a popular alternative in East Asia. Direct comparisons of their efficacy and safety are limited. This retrospective single-center study included 81 critically ill patients receiving CRRT with either NM (n = 31) or RCA (n = 50) from January 2022 to January 2023. The primary outcome was filter lifespan. Secondary outcomes included circuit patency, bleeding events, and metabolic complications. The median filter lifespan was significantly shorter in the NM group compared to the RCA group (23.4 vs. 29.6 h, p = 0.02). The NM group also had a higher rate of unplanned circuit discontinuation (52.3 vs. 39.1%, p = 0.03). Multivariable analysis confirmed RCA was independently associated with a lower risk of circuit failure (HR = 0.44, p = 0.03). Although not statistically significant, trends favored NM regarding metabolic safety, with lower incidences of severe metabolic alkalosis (16.1 vs. 36.0%, p = 0.09) and hypocalcemia (9.7 vs. 26.0%, p = 0.13). RCA demonstrated superior anticoagulation efficacy in prolonging filter survival, while NM may offer a more favorable metabolic safety profile. The choice of anticoagulant should be individualized based on efficacy priorities and metabolic risk.
- 4 November 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2580058
Open AccessEffect of nafamostat mesylate anticoagulation and regional citrate anticoagulation during continuous renal replacement therapy in critically ill patients: a retrospective study of efficacy and safety
Regional citrate anticoagulation (RCA) is recommended for critically ill patients at high bleeding risk undergoing continuous renal replacement therapy (CRRT). Nafamostat mesylate (NM), a short-half-life serine protease inhibitor, is a popular alternative in East Asia. Direct comparisons of their efficacy and safety are limited. This retrospective single-center study included 81 critically ill patients receiving CRRT with either NM (n = 31) or RCA (n = 50) from January 2022 to January 2023. The primary outcome was filter lifespan. Secondary outcomes included circuit patency, bleeding events, and metabolic complications. The median filter lifespan was significantly shorter in the NM group compared to the RCA group (23.4 vs. 29.6 h, p = 0.02). The NM group also had a higher rate of unplanned circuit discontinuation (52.3 vs. 39.1%, p = 0.03). Multivariable analysis confirmed RCA was independently associated with a lower risk of circuit failure (HR = 0.44, p = 0.03). Although not statistically significant, trends favored NM regarding metabolic safety, with lower incidences of severe metabolic alkalosis (16.1 vs. 36.0%, p = 0.09) and hypocalcemia (9.7 vs. 26.0%, p = 0.13). RCA demonstrated superior anticoagulation efficacy in prolonging filter survival, while NM may offer a more favorable metabolic safety profile. The choice of anticoagulant should be individualized based on efficacy priorities and metabolic risk.
- Open Access
- 4 June 2025
- Published by Springer Nature in Critical Care
- Vol. 29 (1) , 1-13
Performance of broad-spectrum targeted next-generation sequencing in lower respiratory tract infections in ICU patients: a prospective observational study
Purpose: Targeted next-generation sequencing (tNGS) has emerged as an advanced diagnostic technique. While tNGS is increasingly recognized as a valuable tool for detecting infections, its most relevant clinical indications remain underdefined. This study aimed to evaluate the clinical utility of tNGS for lower respiratory tract infections (LRTIs). Methods: We conducted a prospective, observational study to evaluate the clinical diagnostic value of broad-spectrum targeted Next-Generation Sequencing (bstNGS) covering 1872 microorganisms in critically ill patients with LRTIs. We compared the microbial detection performance of bstNGS, mNGS, and traditional culture methods in bronchoalveolar lavage fluid (BALF). Additionally, we used the odds ratio (OR) from multiple logistic regression to assess the impact of relevant clinical variables on the detection of pathogens by bstNGS. We also examined the correlation between bstNGS pathogen detection results and clinical outcomes. Results: Between August 23, 2023, and April 24, 2024, samples from 150 patients were analyzed. bstNGS detected 96.33% and 91.15% of the microorganisms discovered by mNGS and culture respectively, and was capable of identifying microorganisms with even lower loads. According to the diagnostic criteria, bstNGS, mNGS, and culture methods detected pathogens in 87.33%, 82.00%, and 46.00% of the samples respectively. Moreover, the NGS methods demonstrated a stronger pathogen detection ability compared to culture (p < 0.05). Further comparing the diagnostic performance of the three methods, bstNGS exhibited higher diagnostic accuracy than both mNGS (90.67% vs 86.00%, p < 0.05) and culture (90.67% vs 49.33%, p < 0.0001). Multivariate analysis revealed that immunocompromise was associated with a lower efficiency of pathogen detection by bstNGS (p = 0.04), while other included clinical features had no significant correlation with bstNGS detection. Additionally, compared with patients in whom no pathogen was detected, patients in whom a pathogen was detected by bstNGS were associated with better outcomes of antibiotic treatment (89.68% vs. 62.50%; OR 7.53, 95% CI 1.41–45.30; p = 0.02). Conclusion: This study shows the effectiveness of bstNGS in detecting pathogens of LRTIs, as well as its value as a potential auxiliary diagnostic method in the ICU.
- 4 June 2025
- Published by Springer Nature in Critical Care
- Vol. 29 (1) , 1-13
Open AccessPerformance of broad-spectrum targeted next-generation sequencing in lower respiratory tract infections in ICU patients: a prospective observational study
Purpose: Targeted next-generation sequencing (tNGS) has emerged as an advanced diagnostic technique. While tNGS is increasingly recognized as a valuable tool for detecting infections, its most relevant clinical indications remain underdefined. This study aimed to evaluate the clinical utility of tNGS for lower respiratory tract infections (LRTIs). Methods: We conducted a prospective, observational study to evaluate the clinical diagnostic value of broad-spectrum targeted Next-Generation Sequencing (bstNGS) covering 1872 microorganisms in critically ill patients with LRTIs. We compared the microbial detection performance of bstNGS, mNGS, and traditional culture methods in bronchoalveolar lavage fluid (BALF). Additionally, we used the odds ratio (OR) from multiple logistic regression to assess the impact of relevant clinical variables on the detection of pathogens by bstNGS. We also examined the correlation between bstNGS pathogen detection results and clinical outcomes. Results: Between August 23, 2023, and April 24, 2024, samples from 150 patients were analyzed. bstNGS detected 96.33% and 91.15% of the microorganisms discovered by mNGS and culture respectively, and was capable of identifying microorganisms with even lower loads. According to the diagnostic criteria, bstNGS, mNGS, and culture methods detected pathogens in 87.33%, 82.00%, and 46.00% of the samples respectively. Moreover, the NGS methods demonstrated a stronger pathogen detection ability compared to culture (p < 0.05). Further comparing the diagnostic performance of the three methods, bstNGS exhibited higher diagnostic accuracy than both mNGS (90.67% vs 86.00%, p < 0.05) and culture (90.67% vs 49.33%, p < 0.0001). Multivariate analysis revealed that immunocompromise was associated with a lower efficiency of pathogen detection by bstNGS (p = 0.04), while other included clinical features had no significant correlation with bstNGS detection. Additionally, compared with patients in whom no pathogen was detected, patients in whom a pathogen was detected by bstNGS were associated with better outcomes of antibiotic treatment (89.68% vs. 62.50%; OR 7.53, 95% CI 1.41–45.30; p = 0.02). Conclusion: This study shows the effectiveness of bstNGS in detecting pathogens of LRTIs, as well as its value as a potential auxiliary diagnostic method in the ICU.